RBC Capital analyst Arun Viswanathan downgraded Pactiv Evergreen (PTVE) to Sector Perform from Outperform with a price target of $18, up from $14, after the company entered into an agreement to merge with Novolex for $18 per share. RBC views the stock as fairly valued at current levels, noting the acquisition by Novolex has shareholder approval.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTVE: